Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AST 201 - Aptamer Sciences

Drug Profile

AST 201 - Aptamer Sciences

Alternative Names: AST 201 Aptamer drug conjugate; AST-201 ApDC; AST201 - Aptamer Sciences

Latest Information Update: 15 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aptamer Sciences
  • Class Amines; Antineoplastics; Cancer vaccines; Deoxyribonucleosides; DNA vaccines; Drug conjugates; Ketones; Pyrimidine nucleosides; Pyrimidines; Vaccines
  • Mechanism of Action Cytidine deaminase inhibitors; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 15 Apr 2024 Phase-I clinical trials in Solid tumours (Late-stage disease) in South Korea (unspecified route) prior to April 2024 (Aptamer Sciences pipeline, April 2024)
  • 27 Mar 2024 Aptamer Sciences plans a phase I trial for Solid tumours in South Korea
  • 12 Mar 2024 Aptamer Sciences files an IND application with the Korean Ministry of Food and Drug Safety in South Korea for Solid tumours
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top